Becker's Spine Review

Becker's July 2021 Spine Review

Issue link:

Contents of this Issue


Page 47 of 47

A bone graft that modulates human immune response. That's how you move the needle. Reducing non-unions is a win-win for surgeons and patients alike. But how can you achieve it? MagnetOs isn't like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology which provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages). *†1 This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft. 2-4 The growing body of science behind MagnetOs is called osteoimmunology. But for patients and surgeons it means one thing: more predictable fusions. * So, are you ready to move the needle? Get in touch with us today at: References: 1. Duan, et al. eCM. 2019;37:60-73. 2. Data on File. 3. Van Dijk, et al. JOR Spine. 2018;e1039. 4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090. *MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit † MagnetOs is not cleared by FDA as an osteoinductive bone graft. Manufactured by Kuros Biosciences BV, Prof Bronkhorstlaan 10, Building 48, 3723 MB Bilthoven, The Netherlands. PROMO/MAG/US/012-21/R00 May '21

Articles in this issue

Links on this page

view archives of Becker's Spine Review - Becker's July 2021 Spine Review